المؤلفون: Cheeseman, MD, Westwood, IM, Barbeau, O, Rowlands, M, Dobson, S, Jones, AM, Jeganathan, F, Burke, R, Kadi, N, Workman, P, Collins, I, van Montfort, RL, Jones, K

وصف الملف: text

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______128::0133f6371bc3d56bc5e234214a979624
https://e-space.mmu.ac.uk/613362/

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: O'Connor S; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK., Le Bihan YV; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK., Liu M; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK., Mak OW; School of Pharmacy and Bioengineering, Keele University, Keele ST5 5BG, UK.; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA., Zazeri G; School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.; Departamento de Física, Instituto de Biociências, Letras e Ciências Exatas (IBILCE), UNESP, Rua Cristovão Colombo 2265, São José do Rio Preto 15054-000, Brazil., Povinelli APR; School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.; Departamento de Física, Instituto de Biociências, Letras e Ciências Exatas (IBILCE), UNESP, Rua Cristovão Colombo 2265, São José do Rio Preto 15054-000, Brazil., Jones AM; School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK., van Montfort R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK., Reynisson J; School of Pharmacy and Bioengineering, Keele University, Keele ST5 5BG, UK., Collins I; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.

المصدر: Molecules (Basel, Switzerland) [Molecules] 2022 Jan 26; Vol. 27 (3). Date of Electronic Publication: 2022 Jan 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE

مواضيع طبية MeSH: HSP70 Heat-Shock Proteins/*antagonists & inhibitors , HSP70 Heat-Shock Proteins/*metabolism , Small Molecule Libraries/*chemistry , Small Molecule Libraries/*pharmacology, Adenosine Triphosphate/metabolism ; Binding Sites/drug effects ; Drug Discovery ; HSP70 Heat-Shock Proteins/chemistry ; Humans ; Ligands ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Protein Domains/drug effects

المؤلفون: Anderhub SJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Mak GW; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Gurden MD; The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Drosopoulos K; The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Walsh K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Woodward HL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Innocenti P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Theofani E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Filosto S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Saville H; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. spiros.linardopoulos@icr.ac.uk.; The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Oct; Vol. 18 (10), pp. 1696-1707.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Cell Cycle Checkpoints*/drug effects, Pyrimidines/*pharmacology , Spindle Apparatus/*metabolism , Triazoles/*pharmacology , Triple Negative Breast Neoplasms/*pathology, Animals ; Biological Availability ; Cell Cycle/drug effects ; Cell Cycle Proteins/antagonists & inhibitors ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Chromosome Segregation/drug effects ; Chromosomes, Human/genetics ; Drug Synergism ; Humans ; Mice ; PTEN Phosphohydrolase/metabolism ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Protein Serine-Threonine Kinases/metabolism ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/metabolism ; Pyrimidines/chemistry ; Spindle Apparatus/drug effects ; Triazoles/chemistry ; Triple Negative Breast Neoplasms/drug therapy

المؤلفون: Woodward HL; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Innocenti P; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Cheung KJ; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Hayes A; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Roberts J; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Henley AT; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Faisal A; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Mak GW; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Box G; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Westwood IM; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom.; Division of Structural Biology , The Institute of Cancer Research , London SW3 6JB , United Kingdom., Cronin N; Division of Structural Biology , The Institute of Cancer Research , London SW3 6JB , United Kingdom., Carter M; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Valenti M; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., De Haven Brandon A; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., O'Fee L; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Saville H; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Schmitt J; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Broccatelli F; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom.; Division of Structural Biology , The Institute of Cancer Research , London SW3 6JB , United Kingdom., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Eccles SA; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom.; The Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research , The Institute of Cancer Research , London SW3 6JB , United Kingdom., Blagg J; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom., Hoelder S; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , London SM2 5NG , United Kingdom.

المصدر: Journal of medicinal chemistry [J Med Chem] 2018 Sep 27; Vol. 61 (18), pp. 8226-8240. Date of Electronic Publication: 2018 Sep 10.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Drug Discovery*, Cell Cycle Proteins/*antagonists & inhibitors , Microsomes, Liver/*metabolism , Protein Kinase Inhibitors/*chemistry , Protein Kinase Inhibitors/*pharmacology , Protein Serine-Threonine Kinases/*antagonists & inhibitors , Protein-Tyrosine Kinases/*antagonists & inhibitors , Pyrimidines/*chemistry , Pyrimidines/*pharmacology , Triazoles/*chemistry , Triazoles/*pharmacology, Animals ; Cell Cycle Proteins/metabolism ; Cells, Cultured ; Clinical Trials, Phase I as Topic ; Female ; Humans ; Male ; Methylation ; Mice ; Microsomes, Liver/drug effects ; Models, Molecular ; Molecular Structure ; Protein Conformation ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Serine-Threonine Kinases/metabolism ; Protein-Tyrosine Kinases/metabolism ; Pyrimidines/pharmacokinetics ; Rats ; Rats, Sprague-Dawley ; Structure-Activity Relationship ; Tissue Distribution ; Triazoles/pharmacokinetics

المؤلفون: Fearon D; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, UK., Westwood IM; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, UK., van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, UK., Bayliss R; Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, UK., Jones K; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, UK. Electronic address: Keith.Jones@icr.ac.uk., Bavetsias V; Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, UK. Electronic address: Vassilios.Bavetsias@icr.ac.uk.

المصدر: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2018 Jul 15; Vol. 26 (11), pp. 3021-3029. Date of Electronic Publication: 2018 Apr 17.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 9413298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3391 (Electronic) Linking ISSN: 09680896 NLM ISO Abbreviation: Bioorg Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Drug Delivery Systems* , Protein Kinase Inhibitors*/chemical synthesis , Protein Kinase Inhibitors*/chemistry , Protein Kinase Inhibitors*/pharmacology, Aminopyridines/*chemistry , Peptide Fragments/*chemical synthesis, Aminopyridines/chemical synthesis ; Aminopyridines/pharmacology ; Crystallography, X-Ray ; Inhibitory Concentration 50 ; Molecular Structure ; Peptide Fragments/chemistry ; Peptide Fragments/pharmacology ; Peptide Library

المؤلفون: Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Mak GWY; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Gurden MD; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK., Xavier CPR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Anderhub SJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Innocenti P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Box G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Valenti MR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., De Haven Brandon AK; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., O'Fee L; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Schmitt J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Woodward HL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., vanMontfort RLM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.

المصدر: British journal of cancer [Br J Cancer] 2017 Apr 25; Vol. 116 (9), pp. 1166-1176. Date of Electronic Publication: 2017 Mar 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cell Cycle Proteins/*genetics , Heterocyclic Compounds, 4 or More Rings/*administration & dosage , M Phase Cell Cycle Checkpoints/*drug effects , Neoplasms/*drug therapy , Protein Kinase Inhibitors/*administration & dosage , Protein Serine-Threonine Kinases/*genetics , Protein-Tyrosine Kinases/*genetics, Animals ; Cell Cycle Proteins/antagonists & inhibitors ; Cell Line, Tumor ; HCT116 Cells ; Humans ; Mice ; Neoplasms/genetics ; Neoplasms/pathology ; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Xenograft Model Antitumor Assays

المؤلفون: Jones AM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom.; Division of Structural Biology, The Institute of Cancer Research, London SW3 6JB, United Kingdom., Osborne JD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Matthews TP; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Cheeseman MD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Rowlands MG; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Jeganathan F; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Lee D; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Kadi N; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Liu M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Richards M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., McAndrew C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Yahya N; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Dobson SE; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom.; Division of Structural Biology, The Institute of Cancer Research, London SW3 6JB, United Kingdom., Jones K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., Collins I; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom., van Montfort RL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom.; Division of Structural Biology, The Institute of Cancer Research, London SW3 6JB, United Kingdom.

المصدر: Scientific reports [Sci Rep] 2016 Oct 06; Vol. 6, pp. 34701. Date of Electronic Publication: 2016 Oct 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: HSP70 Heat-Shock Proteins/*antagonists & inhibitors , HSP70 Heat-Shock Proteins/*chemistry , Quinazolines/*chemical synthesis , Quinazolines/*pharmacology, Amino Acid Sequence ; Binding Sites ; Crystallography, X-Ray ; Drug Design ; Humans ; Ligands ; Models, Molecular ; Protein Binding ; Protein Conformation ; Protein Folding ; Protein Isoforms

المؤلفون: Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KM, Lainchbury M, Brown N, Walton MI, Eve PD, Boxall KJ, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Jamin Y, Robinson SP, Westwood IM, van Montfort RL, Leonard PM; Sareum Ltd. , Cambridge CB22 3FX, U.K., Lamers MB; Sareum Ltd. , Cambridge CB22 3FX, U.K., Reader JC; Sareum Ltd. , Cambridge CB22 3FX, U.K., Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I

المصدر: Journal of medicinal chemistry [J Med Chem] 2016 Jun 09; Vol. 59 (11), pp. 5221-37. Date of Electronic Publication: 2016 May 23.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: 4-Aminopyridine/*analogs & derivatives , Checkpoint Kinase 1/*antagonists & inhibitors , Protein Kinase Inhibitors/*pharmacology , Pyrazines/*pharmacology, 4-Aminopyridine/chemical synthesis ; 4-Aminopyridine/chemistry ; 4-Aminopyridine/pharmacology ; Checkpoint Kinase 1/metabolism ; Dose-Response Relationship, Drug ; Humans ; Models, Molecular ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrazines/chemical synthesis ; Pyrazines/chemistry ; Structure-Activity Relationship